Degenerative valve disease and bioprostheses: Risk assessment, predictive diagnosis, personalised treatments

EPMA Journal

Volumn 2, Issue 1, 2011, Pages 91-105

  Yeghiazaryan, Kristina ^a   Skowasch, Dirk ^a   Bauriedel, Gerhard ^b   Schild, Hans H ^a   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Department of Cardiology   (Germany)

Author keywords

Bioprostheses; Degenerative valve disease; Diabetes; Personalised medicine; Predictive diagnosis; Risk assessment

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE;

AORTA STENOSIS; AORTA VALVE; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; CALCIFICATION; CELL CYCLE REGULATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DEGENERATIVE VALVE DISEASE; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HEART VALVE BIOPROSTHESIS; HUMAN; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTHESIS FAILURE; REVIEW; RISK ASSESSMENT; TISSUE REPAIR; UNINDEXED SEQUENCE; VALVULAR HEART DISEASE;

EID: 79955645592     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-011-0072-3     Document Type: Review

References (82)

1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005; 111: 3316-26.
2. Baumgartner H. Aortic stenosis: medical and surgical management. Heart. 2005; 91: 1483-8.
3. Faggiano P, Antonini-Canterin F, Erlicher A, Romeo C, Cervesato E, Pavan D, et al. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol. 2003; 91: 99-101.
4. Rosenhek R, Maurer G, Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis? Eur Heart J. 2002; 23: 1417-21.
5. Bonow RO, Carabello B, de Leon AC, Edmunds LH, Fedderly BJ, Freed MD, et al. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol. 1998; 32: 1486-588.
6. Srivatsa SS, Harrity PJ, Maercklein PB, Kleppe L, Veinot J, Edwards WD, et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest. 1997; 99: 996-1009.
7. Yeghiazaryan K, Skowasch D, Bauriedel G, Schild HH, Golubnitschaja O. Prediction of degeneration of native and bioprosthetic aortic valves. In: Golubnitschaja O, editor. Predictive Diagnostics & Personalized Treatment: Dream or Reality. New York: Nova Science Publishers; 2009. p. 73-101.
8. Kim KM. Apoptosis and calcification. Scanning Microsc. 1995; 9: 1137-78.
9. Skowasch D, Schrempf S, Wernert N, Steinmetz M, Jabs A, Tuleta I, et al. Cells of primarily extra-valvular origin in degenerative aortic valves and bioprostheses. Eur Heart J. 2005; 26: 2576-80.
10. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993; 91: 1800-9.
11. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001; 104: 921-7.
12. Jian B, Jones PL, Li Q, Mohler 3rd ER, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol. 2001; 159: 321-7.
13. Liu ZP, Olson EN. Suppression of proliferation and cardiomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase. Proc Natl Acad Sci USA. 2002; 99: 2043-8.
14. Bär MDH, Kreuzer J, Cojoc A, Jahn L. Upregulation of embryonic transcription factors in right ventricular hypertrophy. Basic Res Cardiol. 2003; 98: 285-94.
15. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids. 2007; 32: 359-71.
16. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994; 79: 551.
17. Tamamori M, Ito H, Hiroe M, Terada Y, Marumo F, Ikeda MA. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol. 1998; 275: H2036-40.
18. Burton PB, Yacoub MH, Barton PJ. Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development. Eur Heart J. 1999; 20: 604-11.
19. Limana F, Urbanek K, Chimenti S, Quaini F, Leri A, Kajstura J, et al. bcl-2 overexpression promotes myocyte proliferation. Proc Natl Acad Sci USA. 2002; 99: 6257-62.
20. Golubnitschaja O, Yeghiazaryan K, Skowasch D, Schild H, Bauriedel G. p21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification. Amino Acids. 2006; 31: 309-16.
21. Yeghiazaryan K, Bauriedel G, Schild HH, Golubnitschaja O. Prediction of degeneration of native and bioprosthetic aortic valves: issue-related particularities of diabetes mellitus. Infect Disord Drug Targets. 2008; 8: 88-99.
22. Schoen FJ. Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc Pathol. 2005; 14: 189-94.
23. Mercier I, Colombo F, Mader S, Calderone A. Ovarian hormones induce TGF-beta(3) and fibronectin mRNAs but exhibit a disparate action on cardiac fibroblast proliferation. Cardiovasc Res. 2002; 53: 728-39.
24. von Harsdorf R, Hauck L, Mehrhof F, Wegenka U, Cardoso MC, Dietz R. E2F-1 overexpression in cardiomyocytes induces downregulation of p21CIP1 and p27KIP1 and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I. Circ Res. 1999; 85: 128-32.
25. Akli S, Zhan S, Abdellatif M, Schneider MD. E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2. Circ Res. 1999; 85: 319-28.
26. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Cooke JP, Buitrago R, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest. 1997; 99: 1295-301.
27. Schmidt HH, Walter U. NO at work. Cell. 1994; 78: 919-25.
28. Zhuang JC, Wogan GN. Growth and viability of macrophages continuously stimulated to produce nitric oxide. Proc Natl Acad Sci USA. 1997; 94: 11875-80.
29. Lutgens E, de Muinck ED, Kitslaar PJ, Tordoir JH, Wellens HJ, Daemen MJ. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc Res. 1999; 41: 473-9.
30. Sanders DB, Hunter K, Wu Y, Jablonowski C, Bahl JJ, Larson DF. Modulation of the inflammatory response in the cardiomyocyte and macrophage. J Extra-Corpor Technol. 2001; 33: 167-74.
31. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 31-47.
32. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart. 2003; 89: 801-5.
33. Mohler III ER. Mechanisms of aortic valve calcification. Am J Cardiol. 2004; 94: 1396-402.
34. Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med. 1981; 71: 371-84.
35. Niederle B, Stefenelli T, Glogar D, Woloszczuk W, Roka R, Mayr H. Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of a prospective echocardiographic study. Surgery. 1990; 108: 1052-7.
36. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994; 15: 865-70.
37. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007; 50: 1205-13.
38. Golubnitschaja O. Clinical proteomics in application to predictive diagnostics and personalized treatment of diabetic patients. Curr Proteomics. 2008; 5: 35-44.
39. Couet J, Gaudreau M, Lachance D, Plante E, Roussel E, Drolet MC, et al. Treatment of combined aortic regurgitation and systemic hypertension: Insights from an animal model study. Am J Hypertens. 2006; 19: 843-50.
40. Orlowska-Baranowska E, Placha G, Baranowski R, Michalek P, Gora J, Gaciong Z, et al. Can angiotensin II +1675 G/A type 2 receptor gene polymorphism be a marker of left ventricular hypertrophy in patients with aortic stenosis? J Heart Valve Dis. 2007; 16: 495-503.
41. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004; 110: 1180-2.
42. Liebe V, Brueckmann M, Borggrefe M, Kaden JJ. Statin therapy of calcific aortic stenosis: hype or hope? Eur Heart J. 2006; 27: 773-8.
43. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005; 165: 858-62.
44. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104: 2205-9.
45. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002; 40: 1723-30.
46. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110: 1291-5.
47. Skowasch D, Schrempf S, Preusse CJ, Likungu JA, Welz A, Lüderitz B, et al. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart. 2006; 92: 495-8.
48. Chan KL, Teo K, Dumesnil JG, Ni A. ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Circulation. 2010; 121: 306-14.
49. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359: 1343-56.
50. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2006; 106: 2224.
51. Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol. 2004; 94: 1076-80.
52. Lorell BH. Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease. Am J Cardiol. 1999; 83: 48H-52.
53. Yeghiazaryan K, Skowasch D, Bauriedel G, Schild H, Golubnitschaja O. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids. 2007; 32: 109-14.
54. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005; 79: 1072-80.
55. Hattori T, Sakai A, Lhashi K, Kasahara S, Oosawa M. Mitral and aortic valve replacement associated with aortitis syndrome: a case report. Kyobu Geka. 1994; 47: 1016-9.
56. Sugiyama Y, Hirai H, Ohta A, Inoue T, Lee T, Harada M, et al. Severe aortic regurgitation with marked thickening of the aortic annulus: a case report. J Cardiol. 1997; 29: 81-6.
57. Yun KL, Sintek CF, Fletcher AD, Pfeffer TA, Kochamba GS, Hyde MR, et al. Aortic valve replacement with the freestyle stentless bioprosthesis: five-year experience. Circulation. 1999; 100: II17-23.
58. Chen BPC, Li Y-S, Zhao Y, Chen K-D, Li S, Lao J, et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics. 2001; 7: 55-63.
59. Vrandecic M, Fantini FA, Filho BG, de Oliveira OC, da Costa Junior IM, Vrandecic E. Retrospective clinical analysis of stented vs. stentless porcine aortic bioprostheses. Eur J Cardiothorac Surg. 2000; 18: 46.
60. Novaro GM, Pearce GL, Sprecher DL, Griffin BP. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting. J Heart Valve Dis. 2001; 10: 19-24.
61. Horiguchi K, Ohtake S, Matsumiya G, Sawa Y, Nishimura M, Satou H, et al. Aortic valve replacement combined with endoventricular circulatory patch plasty (Dor operation) in a patient with aortic valve stenosis and severe ischemic cardiomyopathy. Ann Thorac Cardiovasc Surg. 2001; 7: 170-4.
62. Murakami T, Kikugawa D, Endou K, Fukuhiro Y, Ishida A, Morita I, et al. Changes in patterns of left ventricular hypertrophy after aortic valve replacement for aortic stenosis and regurgitation with St. Jude Medical cardiac valves. Artif Organs. 2000; 24: 953-8.
63. Taylor PM, Allen SP, Yacoub MH. Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J Heart Valve Dis. 2000; 9: 150-8.
64. Yacoub MH, Kilner PJ, Birks EJ, Misfeld M. The aortic outflow and root: a tale of dynamism and crosstalk. Ann Thorac Surg. 1999; 68: S37-43.
65. Kaden JJ, Vocke DC, Fischer CS, Grobholz R, Brueckmann M, Vahl CF, et al. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol. 2004; 93: 124-30.
66. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107: 1579-85.
67. McGeehan GM, Becherer JD, Bast Jr RC, Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994; 370: 558-61.
68. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994; 370: 555-7.
69. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994; 269: 9352-60.
70. Jamet B, Chabert JP, Metz D, Elaerts J. Acute aortic insufficiency. Ann Cardiol Angeiol (Paris). 2000; 49: 183-6.
71. Ichihara T, Fujii G, Sasaki M, Kawaguchi O, Ueda Y. Clinical characteristics of bicuspid aortic valves in surgical patients. Asian Cardiovasc Thorac Ann. 2006; 14: 210-2.
72. Nollert G, Miksch J, Kreuzer E, Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg. 2003; 126: 965-8.
73. Briand M, Pibarot P, Després JP, Voisine P, Dumesnil JG, Dagenais F, et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation. 2006; 114: I512-7.
74. Colli A, Gherli T, Mestres CA, Pomar JL. Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention? Int J Cardiol. 2007; 116: 144-52.
75. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of infectious endocarditis in patients with type II diabetes mellitus. J Diabetes its Complicat. 2007; 21: 403-6.
76. Gouriet F, Lepidi H, Habib G, Collart F, Raoult D. From cat scratch disease to endocarditis, the possible natural history of Bartonella henselae infection. BMC Infect Dis. 2007; 7: 30.
77. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Després JP, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol. 2006; 47: 2229-36.
78. Baghdasarian SB, Jneid H, Hoogwerf BJ. Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther. 2004; 26: 337-51.
79. Golubnitschaja O. Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA J. 2010; 1: 3-12.
80. George B, Cebioglu M, Yeghiazaryan K. Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J. 2010; 1: 13-8.
81. Abebe W, Mozaffari M. Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools. EPMA J. 2010; 1: 32-45.
82. Sena CM, Bento CF, Pereira P, Seiça R. Diabetes mellitus: new challenges and innovative therapies. EPMA J. 2010; 1: 138-63.